Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

Abstract HER2‐targeted therapy, especially the anti‐HER2 antibody trastuzumab, is standard for HER2‐positive breast cancer; however, its efficacy is limited in a subpopulation of patients. HER3 ligand (heregulin)‐dependent HER2‐HER3 interactions play a critical role in the evasion of apoptosis and a...

Full description

Saved in:
Bibliographic Details
Main Authors: Satomi Watanabe, Kimio Yonesaka, Junko Tanizaki, Yoshikane Nonagase, Naoki Takegawa, Koji Haratani, Hisato Kawakami, Hidetoshi Hayashi, Masayuki Takeda, Junji Tsurutani, Kazuhiko Nakagawa
Format: Article
Language:English
Published: Wiley 2019-03-01
Series:Cancer Medicine
Subjects:
heregulin (HRG)
human epidermal growth factor receptor 2 (HER2)
human epidermal growth factor receptor 3 (HER3)
neuregulin (NRG)
patritumab (U3‐1287)
Online Access:https://doi.org/10.1002/cam4.1995
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.1995

Similar Items